Stockscreener 앱 받기
13.73
2.77%
0.37
시간 외 거래:
13.73
전일 마감가:
$13.36
열려 있는:
$13.32
하루 거래량:
716.79K
Relative Volume:
1.27
시가총액:
$557.65M
수익:
-
순이익/손실:
$-168.05M
주가수익비율:
-2.6764
EPS:
-5.13
순현금흐름:
$-146.15M
1주 성능:
-4.12%
1개월 성능:
-1.29%
6개월 성능:
+26.43%
1년 성능:
-69.08%
1일 변동 폭
$13.19
$13.75
1주일 범위
$13.13
$14.75
52주 변동 폭
$9.12
$72.37
Keros Therapeutics Inc Stock (KROS) Company Profile
명칭
Keros Therapeutics Inc
전화
617-314-6297
주소
1050 WALTHAM STREET, SUITE 302, LEXINGTON, MA
KROS을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
KROS
Keros Therapeutics Inc
|
13.73 | 585.27M | 0 | -168.05M | -146.15M | -5.13 |
|
VRTX
Vertex Pharmaceuticals Inc
|
366.54 | 98.88B | 11.42B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
563.00 | 58.84B | 14.21B | 4.46B | 3.56B | 39.68 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
438.93 | 56.12B | 2.46B | -319.09M | -52.09M | -2.47 |
|
ARGX
Argen X Se Adr
|
661.83 | 41.20B | 3.05B | 1.28B | -614.78M | 19.58 |
|
ONC
Beone Medicines Ltd Adr
|
288.18 | 35.49B | 3.81B | -644.79M | -669.77M | -6.24 |
Keros Therapeutics Inc Stock (KROS) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-06-10 | 다운그레이드 | BofA Securities | Buy → Neutral |
| 2025-01-21 | 다운그레이드 | Cantor Fitzgerald | Overweight → Neutral |
| 2025-01-17 | 다운그레이드 | Wedbush | Outperform → Neutral |
| 2024-12-16 | 다운그레이드 | Guggenheim | Buy → Neutral |
| 2024-12-16 | 재확인 | Oppenheimer | Outperform |
| 2024-12-13 | 재확인 | H.C. Wainwright | Buy |
| 2024-12-12 | 다운그레이드 | BTIG Research | Buy → Neutral |
| 2024-12-12 | 다운그레이드 | TD Cowen | Buy → Hold |
| 2024-12-12 | 다운그레이드 | William Blair | Outperform → Mkt Perform |
| 2024-11-05 | 개시 | Jefferies | Buy |
| 2024-10-24 | 개시 | Cantor Fitzgerald | Overweight |
| 2024-10-16 | 개시 | Scotiabank | Sector Outperform |
| 2024-09-23 | 개시 | Guggenheim | Buy |
| 2024-06-25 | 개시 | Oppenheimer | Outperform |
| 2024-02-21 | 개시 | William Blair | Outperform |
| 2023-12-08 | 개시 | Wells Fargo | Overweight |
| 2023-07-31 | 개시 | Wedbush | Outperform |
| 2023-07-26 | 개시 | BofA Securities | Buy |
| 2023-02-14 | 개시 | Cowen | Outperform |
| 2022-10-18 | 개시 | Truist | Buy |
| 2022-07-26 | 개시 | BTIG Research | Buy |
| 2020-12-08 | 재확인 | H.C. Wainwright | Buy |
| 2020-05-04 | 개시 | H.C. Wainwright | Buy |
| 2020-05-04 | 개시 | Jefferies | Buy |
| 2020-05-04 | 개시 | Piper Sandler | Overweight |
| 2020-05-04 | 개시 | SVB Leerink | Outperform |
모두보기
Keros Therapeutics Inc 주식(KROS)의 최신 뉴스
Keros Therapeutics (NASDAQ:KROS) Price Target Cut to $20.00 by Analysts at HC Wainwright - MarketBeat
XTX Topco Ltd Invests $490,000 in Keros Therapeutics, Inc. (NASDAQ:KROS) - MarketBeat
Keros Therapeutics stock price target lowered to $20 at H.C. Wainwright - Investing.com
Strategic Focus on KER-065 and Leadership Changes Justify Buy Rating for Keros Therapeutics - TipRanks
Keros prioritizes KER-065, pulls plug on cibotercept - The Pharma Letter
Keros Therapeutics’ Workforce Cuts: Potential Savings vs. Strategic Risks - TipRanks
Wedbush Maintains Keros Therapeutics(KROS.US) With Hold Rating, Maintains Target Price $15 - 富途牛牛
Keros Therapeutics to discontinue cibotercept, announces COO departure - TipRanks
Keros Therapeutics, Inc. (NASDAQ:KROS) Holdings Raised by Federated Hermes Inc. - MarketBeat
Keros Therapeutics: Strategic Shift and Organizational Changes Prompt Hold Rating - TipRanks
Keros Therapeutics, Inc. (KROS) Reports Q2 Loss, Beats Revenue Estimates - Yahoo Finance
Keros Therapeutics Announces Strategic Realignment and Leadership Changes - TipRanks
Keros Therapeutics Inc reports results for the quarter ended June 30Earnings Summary - TradingView
Keros Therapeutics Announces Discontinuation of Cibotercept Development and Leadership Changes for Strategic Realignment - Quiver Quantitative
Keros Transforms Pipeline: Focuses All Resources on Promising DMD Drug KER-065 as Phase 2 Trial Approaches - Stock Titan
Keros Therapeutics Reports Second Quarter 2025 Financial Results - GlobeNewswire
Is it the right time to buy Keros Therapeutics Inc. stockGet timely alerts on top market movers - Jammu Links News
Published on: 2025-08-03 17:03:57 - Jammu Links News
Keros Therapeutics Inc. Stock Analysis and ForecastCapitalize on momentum-driven investment opportunities - Jammu Links News
How does Keros Therapeutics Inc. compare to its industry peersBuild wealth faster with consistent investment plans - Jammu Links News
What are analysts’ price targets for Keros Therapeutics Inc. in the next 12 monthsAchieve breakthrough profits with expert advice - Jammu Links News
What are Keros Therapeutics Inc. company’s key revenue driversUnlock exclusive stock market forecasts - Jammu Links News
What are the technical indicators suggesting about Keros Therapeutics Inc.Unlock powerful portfolio optimization tools - Jammu Links News
Keros Therapeutics (KROS) Expected to Announce Quarterly Earnings on Wednesday - MarketBeat
What catalysts could drive Keros Therapeutics Inc. stock higher in 2025Unlock powerful portfolio management tools - jammulinksnews.com
How strong is Keros Therapeutics Inc. company’s balance sheetGain the edge with real-time market data - Jammu Links News
Is Keros Therapeutics Inc. stock overvalued or undervaluedExceptional market performance - Jammu Links News
How volatile is Keros Therapeutics Inc. stock compared to the marketRapid wealth creation - Jammu Links News
Why is Keros Therapeutics Inc. stock attracting strong analyst attentionPowerful market insights - Jammu Links News
Keros Therapeutics, Inc. (NASDAQ:KROS) Receives $30.56 Average Price Target from Analysts - MarketBeat
Does Keros Therapeutics Inc. stock perform well during market downturnsEarnings Report Growth Plan For Smart Trading - Jammu Links News
What is the risk reward ratio of investing in Keros Therapeutics Inc. stockTop Growth Tips For Consistent Profits - Jammu Links News
Corton Capital Inc. Invests $186,000 in Keros Therapeutics, Inc. (NASDAQ:KROS) - MarketBeat
Will Keros Therapeutics Inc. continue its uptrendExit Ready Momentum Stock Watchlist Expanded - metal.it
Can Keros Therapeutics Inc. Outperform Peers After Recent PullbackEarly Entry Tips With Low Risk Zone Shared - metal.it
Bollinger Bands Show Potential Breakout in Keros Therapeutics Inc.AI Screening for Swing Trade Picks Finds Momentum - metal.it
What makes Keros Therapeutics Inc. stock price move sharplyPre Market Trend Scanner From AI Tools - Jammu Links News
Published on: 2025-07-29 02:02:32 - beatles.ru
Is Keros Therapeutics Inc. Stock a Smart Buy in 2025 Investment Analysis InsideShort Term High Return Strategy - metal.it
Published on: 2025-07-27 21:20:25 - Jammu Links News
Keros Therapeutics Inc (KROS) 재무 분석
매출
순이익
현금흐름
주당 순 이익
0.24%
3.39%
자본화:
|
볼륨(24시간):